Table 4.
Non-Compartmental Pharmacokineticsa of [14C]-BaP Following Micro-Dosing with or without 46 or 460 ng [14C]-BaPeq Smoked Salmon or Canned Salmon
| Subject | Fa (fraction absorbed) |
Tmax (hr) |
Cmax (fg/mL) |
AUC0–72hr (fgxhrxmL−1) |
AUC0-∞ (fgxhrxmL−1) |
T1/2 (hr) |
|---|---|---|---|---|---|---|
| Impact of Smoked Salmon Containing 460 ng BaPeq on [14C]-BaP Pharmacokinetics | ||||||
| A | - | 0.75 | 79.2 | 1135 | 2118 | 50 |
| A + 460 ng BaPeq | 0.700 | 8 | 25.3 | 794 | 992 | 30 |
| D | - | 1.5 | 78.1 | 1450 | 1832 | 31 |
| D + 460 ng BaPeq | 0.773 | 8 | 31.9 | 1121 | 2779 | 103 |
| E | - | 2 | 81.6 | 1709 | 3052 | 60 |
| E + 460 ng BaPeq | 1.13 | 2 | 56.7 | 1929 | 2738 | 40 |
| Impact of Smoked Salmon Containing 46 ng BaPeq on [14C]-BaP Pharmacokinetics | ||||||
| B | - | 1.0 | 29.4 | 649 | 1769 | 114 |
| B + 46 ng BaPeq | 1.026 | 3 | 22.8 | 666 | 1880 | 125 |
| C | - | 1.0 | 82.4 | 2060 | 4306 | 79 |
| C + 46 ng BaPeq | 1.121 | 2.5 | 71.1 | 2315 | 4074 | 60 |
| Impact of Canned Salmon on [14C]-BaP Pharmacokinetics | ||||||
| A + Canned Salmon | 0.736 | 8 | 32.8 | 815 | 1108 | 23 |
| D + Canned Salmon | 0.837 | 8 | 39.7 | 1213 | 1699 | 27 |